A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations

The factor VIII (FVIII)-neutralizing antibody (inhibitor) seen in 25%–30% of patients with severe haemophilia A (SHA). Vaccination is a non-genetic risk factor of inhibitor development as ‘danger signal’ which may provide a pro-inflammatory microenvironment to increase FVIII immunogenicity. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zekun, Chen, Zhenping, Cheng, Xiaoling, Wu, Xinyi, Li, Gang, Zhen, Yingzi, Poon, Man-Chiu, Wu, Runhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338642/
https://www.ncbi.nlm.nih.gov/pubmed/32627611
http://dx.doi.org/10.1177/2058738420934618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338642/
https://www.ncbi.nlm.nih.gov/pubmed/32627611
http://dx.doi.org/10.1177/2058738420934618

Ejemplares similares